Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Key Takeaway: Alnylam Pharmaceuticals has announced a strategic collaboration with Viz.ai to enhance care for patients with ATTR-CM. This partnership aims to leverage advanced technology to improve patient outcomes. Additionally, Alnylam is supporting the American Heart Association, indicating a commitment to cardiovascular health.